Jasper Therapeutics Reiterates Going Concern, Reports Rapid Cash Burn and Severe Funding Limitations
JSPR sits 54% above its 52-week low of $0.623.
Summary
Jasper Therapeutics reiterated its going concern warning and reported a rapid cash burn, reducing cash reserves by over 50% in Q1 2026. The company faces severe limitations on its ability to raise capital through public offerings, further jeopardizing its operational runway.
Key Events · Earnings and Guidance · JSPR
-
Reiterated Going Concern Warning
Management concluded that substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months, citing significant losses and negative cash flows.
-
Rapid Cash Depletion
Cash and cash equivalents decreased from $28.7 million as of December 31, 2025, to $14.1 million as of March 31, 2026, representing a burn of over 50% in one quarter.
-
Severe Capital Raising Limitations
Due to a public float below $75 million, the company is limited to raising only one-third of its public float (approximately $25 million) through primary public offerings in any 12-month period, severely restricting access to its $263.5 million shelf registration and $93.5 million ATM program.
-
Significant R&D Program Cuts
Research and development expenses decreased by 64% ($10.3 million) year-over-year, primarily due to workforce reductions and the discontinuation of the Phase 1b asthma study, SCID, and MDS/AML programs.
Analysis · JSPR · Life Sciences
Jasper Therapeutics' financial health is in a critical state, with a reiterated going concern warning and a rapid depletion of cash reserves. The company's cash and cash equivalents dropped by over 50% in a single quarter, indicating a high burn rate. A significant constraint on its ability to raise capital through public offerings, limited to approximately $25 million per year due to its public float, severely restricts access to its existing shelf registration and ATM program. This funding bottleneck, combined with substantial cuts to R&D and ongoing shareholder litigation, creates an extremely high-risk investment scenario.
At the time of this filing, JSPR was trading at $0.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.8M. The 52-week trading range was $0.62 to $7.19. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.